News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


Medsafe revising evaluation, registration fees

Media Release

16 December 2005

Medsafe looks to revise fees for the evaluation and registration of medicines

The agency responsible for regulating medicines is consulting on increasing its fees from 1 July next year for the first time in well over a decade, and in some cases for the first time in 28 years.

The increases reflect the rising costs of regulation as demands on Medsafe to evaluate, audit and monitor the safety of medicines and their manufacture increase.

For instance an application to Medsafe for a new medicine (involving a new chemical entity) typically involves the evaluation of a quarter of a tonne of paperwork.

Under the Medicines Act fees are levied on applications to licence medicine manufacturers and to approve new medicines and clinical trials. Fees are also levied under the Misuse of Drugs Act for applications for licences to, for example, import and export controlled drugs.

Medsafe's Principal Technical Specialist, Dr Stewart Jessamine, says this is the first time since 1977 that fees under the Misuse of Drugs Act have been revised. Fees under the Medicines Act have not been increased since they were first introduced 15 years ago.

"The fees in most cases have been falling well short of covering the actual costs of the complex work related to applications for licences and approval of medicines," Dr Jessamine says.

It is important for New Zealand to meet international best practice standards for the regulation of medicines and also to maintain specialist technical expertise in this area.

The growing gap between the cost of evaluating medicine safety and the amount recovered in fees has meant that approvals for some medicines have been taking as long as three years to process.

Dr Jessamine says it would be tempting to predict that the fee increases will mean shorter times for approving medicines. While that will be true in the long term as capability is strengthened within Medsafe it will be at least a year or 18 months before any improvement can be demonstrated.

"While in most cases the fees for high risk complex activities are going to increase significantly, it is important to note that they still come well under other developed countries, including Britain, the United Sates of America and Australia."

It's important to remember that the work involved in ensuring medicine safety in New Zealand is no less demanding, or important than it is in other overseas jurisdictions, Dr Jessamine says.

Medsafe will begin consultation this week with organisations and individuals affected by the fee increases and feedback from the consultation will be considered before finalising the new fees.

A copy of the discussion document is available on the Medsafe website at


What are the proposed fees?
Current fee
($) ex GST Proposed fee
($) ex GST
Licences under the MODA
Licence to deal in Controlled Drugs 10 840
Licence to possess Controlled Drugs 10 840
Licence to import Controlled Drugs 10 170
Licence to export Controlled Drugs 10 170
Licences under the MA
Licence to Sell Medicines by Wholesale 266 937
Licence to Sell Medicines by Retail 44 750
Licence to Hawk Medicines 62 750
Licence to Operate a Pharmacy 844 917

Current fee
$ (excl GST) Proposed fee
$ (ex GST)
Licence to Manufacture Medicines 3,377 12,222
Licence to Pack Medicines 266 750

Application type Current Fee
($) ex GST Proposed Fee
($) ex GST
Application for consent to supply a new medicine 13,600 109,000
Innovative chemical or biological medicine 13,600 109,000
Generic medicine 6,933 39,000
Non-prescription medicine 6,933 6,800
Application for provisional consent to supply a new medicine 4,444 7,500
Application for approval of a material change to a medicine 1,422 2,844
Major change 1,422 2,844
Minor Change 355 710
Self-assessable change 177 354
Application to approve a clinical trial 2,488 8,750

How do these fees compare with other developed countries?

The revised fee schedule for New Zealand still falls well below the charges of other similar developed countries. Examples of this include:

The proposed New Zealand fee for an application to approve a new innovative product with a new chemical or biological ingredient is $109,000 (excl GST). The equivalent application fee in Australia costs $205,092 (NZD); in the United Kingdom it costs $424,560 (NZD); and in Canada the application fee is $161,590 (NZD).

© Scoop Media

Culture Headlines | Health Headlines | Education Headlines


Howard Davis: Joel Coen's Monochromatic Macbeth

The Bard of Avon may well be smirking up the sleeves of his lace doublet at the irony of Will Smith's Oscar debacle, but now that the initial furore has dissipated, it's worth revisiting the movie for which Denzel Washington was also nominated. More>>

Howard Davis: Kenneth Branagh’s Black & White Belfast

Branagh has assembled a wonderful cast, including Ciarán Hinds, a gently formidable actor who well deserves his Oscar nomination, and Judi Dench, who steals every scene she’s in. More>>

Howard Davis: Dennis Villeneuve’s Dune - A Brief History

So many elements of Herbert’s novel have since become tropes of popular SciFi that Villeneuve’s film sometimes seems deceptively derivative. What makes all this nonsense essential viewing is his astonishing visual sensibility. More>>

Howard Davis: Jill Trevelyan's Rita Angus

Although Angus has become one of Aotearoa’s best-loved painters, the story of her life remained little known and poorly understood before Jill Trevelyan's acclaimed and revelatory biography, which has been republished by Te Papa press. More>>



  • Wellington
  • Christchurch
  • Auckland